

Special Issue

Research and Development of Antibiotics

Message from the Guest Editor

Antimicrobial resistance, especially in the current COVID-19 crisis, has led to the wide spread of highly resistant microorganism strains that threaten the viability of the global health system. While many alternative antimicrobial methods show interesting potential, it is difficult to see how they will be useful in the near future. This particular Special Issue of antibiotics is intended to be the sum of opinions, perspectives, reviews, and unique research manuscripts that provide a view of the current state for developing antibiotics, including inputs from industry and academia. Sharing resources can increase the availability of research on natural products as drug candidates. Product development, innovation and accessibility must be prioritized around the world, along with a research agenda that addresses this issue.

Guest Editor

Prof. Dr. Jesus Simal-Gandara

Department of Analytical and Food Chemistry, Food Science and Technology Faculty, University of Vigo, 32004 Ourense, Spain

Deadline for manuscript submissions

closed (30 September 2021)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/58689

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)